GlycoMimetics:Uproleselan in RR study continues with original even trigger event

GlycoMimetics announced the independent Data Monitoring Committee, DMC, reviewed the interim utility analysis of its Phase 3 study of uproleselan in relapsed/refractory, R/R, acute myeloid leukemia, AML, and recommended the study should continue to the originally planned final overall survival event trigger. "We thank the independent DMC for its recommendation and are strongly encouraged as the blinded pooled survival data continues to show patients living longer than historical benchmarks. Going forward, survival duration for new events in the study will be greater than 14 months since the last patient was randomized, giving us confidence in the potential for uproleselan to improve outcomes for people living with R/R AML," said Harout Semerjian, Chief Executive Officer of GlycoMimetics. "We are proud to be advancing a novel treatment with significant potential to address the urgent unmet medical need in this acute leukemia, and we look forward to continuing the study to the originally planned final overall survival analysis, now expected within the first half of 2024."